Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells

Biochemical and Biophysical Research Communications

Volumn 421, Issue 1, 2012, Pages 140-144

  Yamashita, Takuya ^a,b   Nagano, Kazuya ^a   Kanasaki, So ichiro ^a,b   Maeda, Yuka ^a,b   Furuya, Takeshi ^a,b   Inoue, Masaki ^a   Nabeshi, Hiromi ^b   Yoshikawa, Tomoaki ^a,b   Yoshioka, Yasuo ^a,b   Itoh, Norio ^b   Abe, Yasuhiro ^a   Kamada, Haruhiko ^a,b   Tsutsumi, Yasuo ^a,b   Tsunoda, Shin ichi ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Annexin A4; Biomarker; Cisplatin susceptibility; Malignant mesothelioma; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; LIPOCORTIN 4;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER TISSUE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KNOCKOUT GENE; MALIGNANT MESOTHELIOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REGULATORY MECHANISM; TREATMENT RESPONSE; WESTERN BLOTTING;

ANNEXIN A4; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASMS, MESOTHELIAL;

EID: 84860330034     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.144     Document Type: Article

References (21)

1. Rom W.N., Travis W.D., Brody A.R. Cellular and molecular basis of the asbestos-related diseases. Am. Rev. Respir. Dis. 1991, 143:408-422.
2. Heintz N.H., Janssen-Heininger Y.M., Mossman B.T. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am. J. Respir. Cell Mol. Biol. 2010, 42:133-139.
3. Consensus Report: Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand. J. Work Environ. Health 23 (1997) 311-316.
4. Yan T.D., Welch L., Black D., Sugarbaker P.H. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann. Oncol. 2007, 18:827-834.
5. Chailleux E., Pioche D., Chopra S., Dabouis G., Germaud P., De Lajartre A.Y., De Lajartre M. Prognostic factors in diffuse malignant pleural mesothelioma: a study of 167 patients. Chest 1988, 93:159-162.
6. Sridhar K.S., Doria R., Raub W.A., Thurer R.J., Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992, 70:2969-2979.
7. Markman M., Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J. Cancer Res. Clin. Oncol. 1992, 118:547-550.
8. Eltabbakh G.H., Piver M.S., Hempling R.E., Recio F.O., Intengen M.E. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J. Surg. Oncol. 1999, 70:6-12.
9. Berghmans T., Paesmans M., Lalami Y., Louviaux I., Luce S., Mascaux C., Meert A.P., Sculier J.P. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung. Cancer 2002, 38:111-121.
10. Lerner H.J., Schoenfeld D.A., Martin A., Falkson G., Borden E. Malignant mesothelioma: The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983, 52:1981-1985.
11. Mintzer D.M., Kelsen D., Frimmer D., Heelan R., Gralla R. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep. 1985, 69:711-712.
12. Zidar B.L., Green S., Pierce H.I., Roach R.W., Balcerzak S.P., Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988, 6:223-226.
13. Han E.K., Tahir S.K., Cherian S.P., Collins N., Ng S.C. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br. J. Cancer 2000, 83:83-88.
14. Kim A., Enomoto T., Serada S., Ueda Y., Takahashi T., Ripley B., Miyatake T., Fujita M., Lee C.M., Morimoto K., Fujimoto M., Kimura T., Naka T. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int. J. Cancer 2009, 125:2316-2322.
15. Kaetzel M.A., Hazarika P., Dedman J.R. Differential tissue expression of three 35-kDa annexin calcium-dependent phospholipid-binding proteins. J. Biol. Chem. 1989, 264:14463-14470.
16. Zanotti G., Malpeli G., Gliubich F., Folli C., Stoppini M., Olivi L., Savoia A., Berni R. Structure of the trigonal crystal form of bovine annexin IV. Biochem. J. 1998, 329:101-106.
17. Kaetzel M.A., Mo Y.D., Mealy T.R., Campos B., Bergsma-Schutter W., Brisson A., Dedman J.R., Seaton B.A. Phosphorylation mutants elucidate the mechanism of annexin IV-mediated membrane aggregation. Biochemistry 2001, 40:4192-4199.
18. Hill W.G., Kaetzel M.A., Kishore B.K., Dedman J.R., Zeidel M.L. Annexin A4 reduces water and proton permeability of model membranes but does not alter aquaporin 2-mediated water transport in isolated endosomes. J. Gen. Physiol. 2003, 121:413-425.
19. Kaetzel M.A., Chan H.C., Dubinsky W.P., Dedman J.R., Nelson D.J. A role for annexin IV in epithelial cell function. Inhibition of calcium-activated chloride conductance. J. Biol. Chem. 1994, 269:5297-5302.
20. Sohma H., Creutz C.E., Gasa S., Ohkawa H., Akino T., Kuroki Y. Differential lipid specificities of the repeated domains of annexin IV. Biochim. Biophys. Acta 2001, 1546:205-215.
21. Piljic A., Schultz C. Annexin A4 self-association modulates general membrane protein mobility in living cells. Mol. Biol. Cell 2006, 17:3318-3328.